2. Signaling Pathways
  3. Immunology/Inflammation
  4. Complement System

Complement System

Complement System

Related Products

PDF 0.66 MB

The complement system, composed of more than 30 serum and cell surface components, is collaborating in recognition and elimination of pathogens as a part of both the innate and acquired immune systems. Once the complement system is activated, a chain of reactions involving proteolysis and assembly occurs, resulting in cleavage of the third complement component (C3). The cascade up to C3 cleavage is called the activation pathway. There are three activation pathways: the classical, lectin, and alternative pathways.

The complement cascade is a dual-edged sword, causing protection against bacterial and viral invasion by promoting phagocytosis and inflammation. Pathologically, complement can cause substantial damage to blood vessels (vasculitis), kidney basement membrane and attached endothelial and epithelial cells (nephritis), joint synovium (arthritis), and erythrocytes (hemolysis) if it is not adequately controlled.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-147586
    C5aR-IN-2
    C5aR-IN-2 is a potent inhibitor of C5aR. Increased level of C5a has been associated with disorders such as autoimmune disorders and inflammatory disorders. C5aR-IN-2 has the potential for the research of inflammation diseases (extracted from patent WO2022028586A1, compound 49).
    C5aR-IN-2
  • HY-P1398A
    Compstatin control peptide TFA
    		Control
    Compstatin control peptide TFA is a negative control of Compstatin (HY-P1036). Compstatin is a potent complement system C3 inhibitor.
    Compstatin control peptide TFA
  • HY-W049802
    N-((Allyloxy)carbonyl)-N-methyl-L-alanine
    		Inhibitor
    N-((Allyloxy)carbonyl)-N-methyl-L-alanine is a Alanine derivative. N-((Allyloxy)carbonyl)-N-methyl-L-alanine can be used for the synthesis of inhibitors of complement factor D. Complement factor D inhibitors can be used in the research of immune system related disease.
    N-((Allyloxy)carbonyl)-N-methyl-L-alanine
  • HY-E70533
    C1r Proenzyme
    C1r proenzyme, the native form of C1r enzyme, is an inactive zymogen until C1 is activated. C1r is activated when C1 binds to and is activated by antibodies bound to antigens (immune complexes) yielding C1r enzyme.
    C1r Proenzyme
  • HY-P99767
    Olendalizumab
    		Inhibitor
    Olendalizumab (ALXN1007) is a mouse-derived and humanized IgG2-G4-κ antibody, targeting to Complement protein C5a (Ki=60 pM). Olendalizumab targets the complement inflammatory pathway. Moreover, Olendalizumab can be used for research of complement mediated disorder caused by corona virus.
    Olendalizumab
  • HY-P99636
    Gavilimomab
    Gavilimomab (ABX-CBL) is an IgM murine monoclonal antibody that recognizes CD147 on the cell surface and initiates cell killing through complement-mediated lysis. Gavilimomab can be used for the research of graft-versus-host disease (GVHD).
    Gavilimomab
  • HY-B0579S1
    Cyclosporin A-d3
    Cyclosporin A-d3 is the d3-labeled Cyclosporin A (HY-B0579)[1].
    Cyclosporin A-d<sub>3</sub>
  • HY-147605
    Factor B-IN-3
    		Inhibitor
    Factor B-IN-3 (Example 3 target compound) is a potent complement factor B inhibitor. Factor B-IN-3 can be used for the research of diseases related to inflammation and immunity.
    Factor B-IN-3
  • HY-P991067
    Vensobafusp alfa
    		Inhibitor
    Vensobafusp alfa (KP-104) is a fusion protein composed of an IgG4 monoclonal antibody directed against terminal complement protein C5 fused to the complement factor H 1-5 domain (FH1-5). Vensobafusp alfa shows anti-inflammatory and immunomodulatory activities. The isotype control for Vensobafusp alfa can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003)..
    Vensobafusp alfa
  • HY-16384
    L-156602
    		Antagonist
    L-156602 is a C5a receptor antagonist. L-156602 inhibits inflammation, and the migration of monocytes and neutrophils to the infiltrating site in mouse inflammatory models. L-156602 suppresses the efferent phase of delayed-type hypersensitivity (DTH).
    L-156602
  • HY-147604
    Factor B-IN-2
    		Inhibitor
    Factor B-IN-2 (Example 1 target compound) is a potent complement factor B inhibitor, with an IC50 of 1.5 μM. Factor B-IN-2 can be used for the research of diseases related to inflammation and immunity.
    Factor B-IN-2
  • HY-163062
    Tubulin/NRP1-IN-1
    		Inhibitor
    Tubulin/NRP1-IN-1 (compound TN-2) is a dual inhibitor of Tubulin and NRP1 with IC50s of 0.71 and 0.85 μM, respectively. Tubulin/NRP1-IN-1 significantly inhibits the viability of prostate tumor cell lines and induces apoptosis.
    Tubulin/NRP1-IN-1
  • HY-163379
    C5aR1 antagonist 2
    		Antagonist
    C5aR1 antagonist 2 (Compound 6a) is an orally active C5a receptor 1 (C5aR1) antagonist that shows efficacy in inhibiting the C5a-induced neutrophil count increase. C5aR1 antagonist 2 is potent in the DISCO and migration assays, with IC50 values of 21 and 3 nM, respectively. C5aR1 antagonist 2 can be used for the research of acute and chronic inflammatory diseases.
    C5aR1 antagonist 2
  • HY-N7166
    3-O-(2'E,4'Z-Decadienoyl)ingenol
    		Inhibitor
    3-O-(2'E,4'Z-Decadienoyl)ingenol is a natural diterpene that exhibits significant anticomplement activity with an IC50 of 89.5 μM.
    3-O-(2'E,4'Z-Decadienoyl)ingenol
  • HY-172239
    Tarvicopan
    		Inhibitor
    Tarvicopan is an inhibitor for complement factor D.
    Tarvicopan
  • HY-P990378
    Anti-Complement Factor P/Properdin Antibody
    		Inhibitor
    Anti-Complement Factor P/Properdin Antibody is a humanized antibody expressed in CHO, targeting Complement Factor P/Properdin. Anti-Complement Factor P/Properdin Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-Complement Factor P/Properdin Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-Complement Factor P/Properdin Antibody
  • HY-14648S1
    Dexamethasone-d5-1
    		Inhibitor
    Dexamethasone-d5-1 is deuterium labeled Dexamethasone. Dexamethasone (Hexadecadrol) is a glucocorticoid receptor agonist. Dexamethasone also significantly decreases CD11b, CD18, and CD62L expression on neutrophils, and CD11b and CD18 expression on monocytes. Dexamethasone is highly effective in the control of COVID-19 infection. Dexamethasone inhibits production of exosomes containing inflammatory microRNA-155 in lipopolysaccharide-induced macrophage inflammatory responses.
    Dexamethasone-d<sub>5</sub>-1
  • HY-17627R
    Avacopan (Standard)
    		Inhibitor
    Avacopan (Standard) is the analytical standard of Avacopan. This product is intended for research and analytical applications. Avacopan (CCX168) is a potent, selective and orally available complement 5a receptor (C5aR) inhibitor with an IC50 of 0.1 nM.
    Avacopan (Standard)
  • HY-P10639A
    C5aR2 agonist P32 acetate
    		Agonist
    C5aR2 agonist P32 (Ac-RHYPYWR-OH) acetate is a C5aR2-selective agonist. C5aR2 agonist P32 acetate has been shown to elicit multiple immunomodulatory activities, both by down-regulating the C5aR1-mediated cell signalling, and acting in a C5aR1-independent fashion, in vitro and in vivo.
    C5aR2 agonist P32 acetate
  • HY-P3502B
    Zilucoplan (PEG2)
    		Inhibitor
    Zilucoplan (PEG2) is a Zilucoplan (HY-P3502) derivative, where the linker section replaces PEG24 by PEG2. Zilucoplan is a potent complement component 5 (C5) inhibitor.
    Zilucoplan (PEG2)
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity